Welcome to our dedicated page for 180 Life Sciences news (Ticker: ATNF), a resource for investors and traders seeking the latest updates and insights on 180 Life Sciences stock.
180 Life Sciences Corp. Common Stock (symbol: ATNF) represents a pioneering clinical-stage biotechnology company based in Menlo Park, California. The company focuses on developing innovative therapeutics to address unmet medical needs in chronic pain, inflammation, and fibrosis.
The company has several key product development platforms currently in Phase IIb/III clinical trials:
- Fibrosis and Anti-TNF Platform: This platform targets the treatment of fibrosis and anti-tumor necrosis factors, a major cause of inflammation.
- Synthetic Cannabidiol (CBD) Analogs Platform: This platform includes man-made derivatives of CBD designed to offer therapeutic benefits.
- α7nAChR Platform: Focused on the alpha 7 nicotinic acetylcholine receptor, which plays a role in modulating inflammation and pain.
180 Life Sciences Corp. is committed to advancing its drug candidates through robust clinical trials and cutting-edge research. From addressing postoperative pain relief with orally absorbed CBD tablets to combating chronic inflammation and fibrosis, the company's innovative approach highlights its significance in the biotechnology landscape.
The company’s recent achievements include a notable presentation by Dr. Michael J. Alaia at the 2022 American Academy of Orthopaedic Surgeons Annual Meeting. The talk focused on the efficacy of CBD tablets for postoperative pain relief, showcasing the potential impact of 180 Life Sciences Corp.'s therapies.
For more information, investors can contact Jason Assad, Director of Investor Relations, at jassad@180lifesciences.com.
180 Life Sciences Corp (NASDAQ:ATNF) has announced the appointment of Vaclav Vincalek as Senior Technology Consultant to oversee the integration of their recently acquired Gaming Technology Platform. Vincalek, an experienced technologist with expertise in technical leadership and strategy, will work with management to establish the company's online gaming infrastructure. This strategic move represents the company's effort to expand its presence in the gaming industry and enhance its technological capabilities. The integration is expected to strengthen the company's infrastructure and create new growth opportunities.
180 Life Sciences Corp. (NASDAQ:ATNF) has appointed Jay Goodman to its Board of Directors as an independent member and Audit Committee member. Goodman brings over a decade of expertise in SaaS and iGaming industries, with seven years in executive leadership. He currently serves as Sales Director for Asia Pacific and Japan at Docker, Inc. His prior experience includes roles at Confluent, Skywind Games, Dropbox, Hootsuite, and OFX. The appointment aligns with 180's strategy to expand into the online gaming market, according to Interim CEO Blair Jordan.
180 Life Sciences Corp. (NASDAQ:ATNF) announced its strategic entry into the online gaming industry with a newly acquired blockchain-based gaming platform. The company plans to establish blockchain-based B2C online casinos and expand into a B2B model, offering technology solutions for gaming operators worldwide. Key features of the platform include:
1. Blockchain casino operations back-end
2. Seamless blockchain to FIAT exchange technology
3. Blockchain API technology
4. Player account management
5. Loyalty systems for blockchain users
6. Affiliate tracking system
The company aims to launch operations in high-growth international markets, focusing on jurisdictions like Germany, Brazil, India, Canada, and Colombia. 180 Life Sciences Corp. targets having its first online casino fully operational by the end of Q1 2025, subject to funding and successful implementation of its commercialization strategy.
180 Life Sciences Corp. (NASDAQ:ATNF) has regained compliance with Nasdaq's minimum stockholders' equity rule and announced a strategic shift towards the global iGaming sector. The company has acquired a leading iGaming platform technology, incorporating blockchain and digital payment solutions. This move positions 180 to capitalize on the rapidly growing iGaming market, projected to reach $160 billion by 2026.
The company's platform will accept both cryptocurrency and fiat currency, offering flexibility to players. 180 expects to launch the platform in the first quarter of 2025. While focusing on this new venture, the company will continue to advance its legacy biotechnology programs. However, 180 remains out of compliance with Nasdaq's audit committee requirements and is seeking qualified independent directors to address this issue.
180 Life Sciences Corp. (NASDAQ:ATNF) announces a strategic shift into the global iGaming market with the acquisition of a comprehensive Gaming Technology Platform. The platform includes blockchain casino operations back-end, seamless blockchain-to-FIAT exchange technology, and player account management systems. The company issued 1 million shares of Series B Convertible Preferred Stock and warrants for 3 million common shares as consideration.
Additionally, 180 reports positive study results for its CBD pill formulation, showing faster absorption and improved bioavailability compared to the FDA-approved Epidiolex. The company also strengthened its balance sheet by settling legacy liabilities at substantial discounts and resolving certain litigation matters.
Management believes the acquisition will help meet Nasdaq's minimum stockholder equity requirements for continued listing, though official confirmation is pending. The global online gaming sector is projected to reach $97 billion in 2024 and grow to nearly $133 billion by 2029.
180 Life Sciences Corp has appointed Omar Jimenez as its new Chief Financial Officer, effective September 30, 2024. Jimenez, already a director of the company, brings extensive financial expertise and experience to the role. He has previously worked in high-profile positions at companies such as Golden Matrix Group, Alfadan, and Monaker Group.
CEO Blair Jordan expressed excitement about Jimenez joining the executive team, citing his financial expertise and forward-thinking approach as ideal for guiding the company through its growth phase. Jimenez holds a BBA in Accounting and Finance from the University of Miami and an MBA from Florida International University. He replaces former CFO Ozan Pamir.
180 Life Sciences Corp. (NASDAQ: ATNF) announced positive topline results from a clinical pharmacology study comparing two solid formulations of cannabidiol (CBD) with the FDA-approved drug Epidiolex. The study, conducted with 12 volunteers, showed that one of the solid forms was absorbed faster and exhibited higher maximal levels compared to Epidiolex. Both solid formulations were well-tolerated.
The company developed 'ProNanoLipospheres' (PNL), a mixture of over-the-counter components that form droplets absorbed from the gastrointestinal tract into blood. This new formulation could potentially advance testing of CBD in other indications such as pain, PTSD, and head trauma. The solid formulation may provide medical professionals with expanded options to prescribe CBD in a precisely dosed, high uptake pill format.
180 Life Sciences Corp. (NASDAQ: ATNF) has received an extension from the Nasdaq Listing Qualifications Panel to regain compliance with continued listing requirements. The company now has until September 20, 2024 to meet the minimum stockholders' equity requirement of $2.5 million. This extension allows 180 Life Sciences to continue trading on Nasdaq while working to meet the Equity Rule.
The company had previously received a delist determination letter on May 14, 2024, but appealed the decision. While the Hearings Panel has granted this extension, there is no guarantee that 180 Life Sciences will meet the deadlines or conditions imposed. The Nasdaq Listing and Hearing Review Council may also review the decision within 45 calendar days.
180 Life Sciences announced that Nasdaq's Hearings Panel has granted the company an extension to regain compliance with Nasdaq's continued listing requirements, particularly the minimum stockholders’ equity rule of $2.5 million, by July 31, 2024. The company was initially notified of non-compliance on November 15, 2023, and was unable to meet the equity requirement by the extended deadline of May 13, 2024. Consequently, a delist determination was issued on May 14, 2024. Following an appeal, the delisting action was stayed pending the Hearings Panel's decision, which has now granted the company additional time to comply. However, there is no guarantee that the company will meet these requirements.
FAQ
What is the current stock price of 180 Life Sciences (ATNF)?
What is the market cap of 180 Life Sciences (ATNF)?
What does 180 Life Sciences Corp. specialize in?
Where is 180 Life Sciences Corp. headquartered?
What are the key platforms of 180 Life Sciences Corp.?
What stage are the company's product development platforms in?
Who can be contacted for investor relations?
What is the focus of the recent talk presented by Dr. Michael J. Alaia?
What is the company's ticker symbol?
What unmet medical needs does 180 Life Sciences Corp. aim to address?
What is the significance of the α7nAChR platform?
How can I stay updated with the latest news about 180 Life Sciences Corp.?
